SUBSCRIBE
SUBSCRIBE
News   Policy

Dendreon Corporation Shares Halted Ahead of FDA Meeting

March 29, 2007 | 
1 min read
SAN FRANCISCO (MarketWatch) -- Shares of Dendreon Corp. were halted before the start of trading Thursday, ahead of a Food and Drug Administration advisory committee meeting to evaluate Provenge, the company's experimental prostate-cancer drug.

>>> Discuss This Story

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
complex messy management, bureaucracy,red tape,organization and innovation,business disruption, complicated business process
Regulatory
Absence of Bureaucracy at FDA Is Shooting Pharma in the Foot
December 12, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
December 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie
Two businessmen negotiating with big speech bubbles
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
December 9, 2025
 · 
2 min read
 · 
Heather McKenzie